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CD4 T cells play a central role as helper cells in adaptive immunity. Presentation of exoge-
nous antigens in MHC class II by professional antigen-presenting cells is a crucial step
in induction of specific CD4 T cells in adaptive immune responses. For efficient induction
of immunity against intracellular threats such as viruses or malignant transformations,
antigens fromHLA class II-negative infected or transformed cells need to be transferred to
surrounding antigen-presenting cells to allow efficient priming of naive CD4 T cells. Here
we show indirect antigen presentation for a subset of natural HLA class II ligands that
are created by genetic variants and demonstrated that (neo)antigens can be transferred
between cells by extracellular vesicles. Intercellular transfer by extracellular vesicles was
not dependent on the T-cell epitope, but rather on characteristics of the full-length protein.
This mechanism of (neo)antigen transfer from HLA class II-negative cells to surrounding
antigen-presenting cells may play a crucial role in induction of anti-tumor immunity.
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Introduction
CD4 T cells play a central role as helper cells in adaptive immu-
nity [1]. MHC class II positive macrophages, B-cells and dendritic
cells are well equipped to take up, process and present exogenous
antigens in their MHC class II molecules, and priming of naive
CD4 T cells by these professional antigen presenting cells (APC) is
a crucial step in efficient induction of immune responses [2]. Upon
recognition of epitopes in MHC class II molecules, antigen-specific
CD4 T cells become activated and secrete cytokines, thereby
providing help to induction and maintenance of CD8 cytotoxic
T-lymphocytes [1, 3], stimulation of B-cells to produce antibodies
[4], maturation of dendritic cells [1] and induction of delayed type
hypersensitivity reactions by activation of macrophages [4, 5]. As
such, CD4 T-helper cells are crucial in eliciting potent immunity
against exogenous pathogens.
For efficient induction of immunity against intracellular
threats, such as viruses or malignant transformations, intracellular
antigens from HLA class II-negative infected or transformed cells
need to be transferred to surrounding APC in order to prime naive
CD4 T cells. This concept of antigen transfer is well known from
solid organ transplantation where presentation of donor antigens
on recipient APC has been linked to chronic rejection [6, 7]. Also
in mice after MHC-matched allogeneic bone marrow transplanta-
tion, donor APC presenting recipient antigens have been shown to
stimulate CD4 T cells andmediate Graft-versus-Host disease [8]. A
similar mechanism in which CD4 T-helper cells are primed by APC
presenting differentiation antigens taken up from highly special-
ized HLA class II-negative tissues may explain the predisposition
of human individuals with specific HLA class II alleles to develop
autoimmune diseases [9]. Finally, in tumor immunology, indirect
presentation of tumor-associated antigens by professional APC has
been shown to induce beneficial immune responses in which MHC
class II-negative tumors can be rejected in a CD4 T-cell dependent
fashion [10–12].
In addition to tumor-associated antigens, which are self-
proteins that are overexpressed in tumors, HLA ligands created by
genetic variants can be recognized by the immune system and lead
to potent anti-tumor responses. These non-self or neoantigens can
be encoded by genetic polymorphisms that are targeted by donor
T cells after allogeneic stem cell transplantation [13–15] or by
somatic mutations that are recognized by autologous T cells in
non-transplanted cancer patients [16, 17]. Remarkably, HLA class
II-restricted neoantigens have been identified as T-cell targets in
patients with HLA class II-negative solid tumors [17], strongly sug-
gesting that also neoantigens can be transferred from tumor cells
to HLA class II-positive APC for induction of specific CD4 T cells.
We here show indirect antigen presentation for a subset of natu-
ral HLA class II ligands that are created by genetic variants and
demonstrate that these antigens can be transferred between cells
by full-length proteins that are secreted in extracellular vesicles
(EV). This mechanism of (neo)antigen transfer from HLA class II-
negative tumor cells to surrounding APC via EV may play a crucial
role in induction of anti-tumor immunity.
Results
Intercellular transfer of natural HLA class II ligands
that are created by genetic variants
To investigate the occurrence of indirect antigen presentation, we
selected 6 HLA class II ligands encoded by genetic polymorphisms
that are targeted by donor CD4 T cells after allogeneic hematopoi-
etic stem cell transplantation. The antigens were derived from
cytosolic kinases (PTK2B and PI4K2B), membrane proteins (LY75
and MR1), cytosolic enzyme (MTHFD1) and nuclear/cytosolic
RNA helicase (DBY). The antigens were restricted by differ-
ent HLA-DR and -DQ alleles: DRB1*03:01/A*01:02 (MTHFD1),
DRB1*13:01/A*01:02 (LY75), DRB3*01:01/A*01:02 (PTK2B),
DRB3*02:02/A*01:02 (MR1), DQB1*06:03/A*01:03 (PI4K2B)
and DQB1*05:01/A*01:01 (DBY). Five proteins (LY75, MR1,
PTK2B, PI4K2B and MTHFD1) were identified as minor histo-
compatibility antigens targeted by specific CD4 T cells in a female
patient after allogeneic stem cell transplantation with her HLA-
matched sister [14, 15], whereas the remaining protein (DBY) is
encoded on the Y-chromosome and recognized by CD4 T cells in
a male patient after allogeneic stem cell transplantation with his
HLA-identical sister [18].
To investigate whether indirect antigen presentation occurs
for all 6 natural HLA class II ligands or for a subset of these anti-
gens, antigen-positive donor cells lacking the relevant HLA class
II restriction alleles (Agpos/HLAneg donor cells) were co-cultured
with antigen-negative acceptor cells that were positive for the HLA
class II restriction alleles (Agneg/HLApos acceptor cells). In our first
experiments, EBV-B cells endogenously expressing the antigens of
interest were used as donor cells. As acceptor cells, HeLa cells
transduced with the relevant HLA class II restriction alleles were
used. After co-culturing, T-cell recognition was observed for 3
antigens (PTK2B, MTHFD1 and DBY), whereas donor and accep-
tor cells were not or hardly recognized by the respective T cells
when analyzed separately (Fig. 1A, Supporting Information Figs. 1
and 2). Further analysis revealed that direct T-cell contact was not
required, since the three cytosolic proteins were efficiently trans-
ferred between cells via culture supernatants (Fig. 1B). Moreover,
antigen transfer did not occur when flowthroughs of culture super-
natants from 10, 30 or 100 kDa filters were loaded, indicating that
intercellular transfer was mediated by particles >100 kDa.
In the experiments above, HeLa cells transduced with HLA
class II were used as acceptor cells. HeLa cells are negative
for all antigens analyzed except for PI4K2B. Since endogenous
PI4K2B expression in HeLa complicated data interpretation for
this antigen, we also developed a reversed system in which HLA
class II-negative HeLa cells transduced with wild-type PTK2B or
PI4K2B were used as donor cells and antigen-negative EBV-B
cells endogenously expressing the relevant HLA class II alleles
as acceptor cells. Using this reversed system, we confirmed that
the HLA class II ligand of PTK2B can be transferred between
cells, whereas no transfer was observed for the antigen of PI4K2B
(Fig. 1C).
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Figure 1. Intercellular transfer of the natural HLA class II ligand of PTK2B. (A) EBV-B cells endogenously expressing the PTK2B antigen, but lacking
the relevant HLA-DRB3*01:01/A*01:02 restriction allele (Agpos/HLAneg donor cells) were co-cultured with antigen-negative HeLa cells that were
transduced with HLA-DRB3*01:01/A*01:02 (Agneg/HLApos acceptor cells). After overnight coculture, PTK2B-specific T cells were added and IFN-γ
release was measured by ELISA. As positive control, HLA class II-transduced HeLa cells were exogenously loaded with recombinant PTK2B. Results
of duplicate wells pooled from three independent experiments represented by open, gray and black dots are shown. (B) Culture supernatants from
antigen-positive EBV-B donor cells lacking the relevant HLA-DRB3*01:01/A*01:02 restriction allele were centrifuged at 300 × g to remove viable cells
and cell debris, and loaded on antigen-negative HeLa cells transducedwith HLA-DRB3*01:01/A*01:02. In addition, culture supernatants were passed
through filters to remove proteins and particles with sizes >10, 30 or 100 kDa, and flow throughs were loaded on HeLa acceptor cells. Antigen
uptake, processing and presentation into HLA class II was tested by measuring recognition by PTK2B-specific T cells in IFN-γ ELISA. Results of
duplicate or quadruplicate wells pooled from three independent experiments represented by open, gray and black dots are shown for culture
supernatants and flow throughs of 30 kDa filters. (C) HLA class II-negative HeLa cells transduced with wild-type PTK2B or PI4K2B (Agpos/HLAneg
donor cells) were cocultured with antigen-negative EBV-B cells endogenously expressing the HLA-DRB3*01:01/A*01:02 and DQB1*06:03/A*01:03
(Agneg/HLApos acceptor cells) restriction alleles for PTK2B and PI4K2B, respectively. After overnight coculture, T cells for PTK2B or PI4K2B were
added and IFN-γ release was measured by ELISA. Results of duplicate or triplicate wells pooled from three independent experiments represented
by open, gray and black symbols are shown for T cells for PTK2B (dots; left) and PI4K2B (triangles; right).
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Intercellular transfer of the HLA class II PTK2B ligand
is mediated by its full-length protein
To investigate whether indirect antigen presentation is an intrin-
sic property of the HLA class II ligand or whether other pro-
tein sequences are involved, we made retroviral constructs for
full-length PTK2B and PI4K2B in which the T-cell epitopes were
exchanged between both proteins. Chimera A encoded full-length
PI4K2B with the T-cell epitope of PTK2B, whereas chimera B
encoded full-length PTK2B with the T-cell epitope of PI4K2B (Fig.
2A). Direct presentation of the PTK2B antigen after retroviral
transfer of chimera A in antigen-negative EBV-B cells expressing
the relevant HLA class II restriction allele was in the same range
as wild-type PTK2B (Fig. 2B), confirming proper processing and
presentation of the PTK2B epitope when supplied in the context
of the PI4K2B protein. Direct presentation of the PI4K2B anti-
gen after retroviral transfer of chimera B was also detected albeit
with different efficiencies. To investigate indirect antigen presen-
tation, antigen-negative EBV-B cells expressing the relevant HLA
class II restriction alleles (acceptor cells) were loaded with culture
supernatants from HLA class II-negative HeLa cells transduced
with wild-type PTK2B, wild-type PI4K2B, chimera A or chimera
B. When supplied in their wild-type protein context, we again
demonstrated indirect presentation of PTK2B, but not for PI4K2B
(Fig. 2C). However, in contrast to wild-type PI4K2B, indirect pre-
sentation of the PI4K2B epitope was observed when supplied in
the context of full-length PTK2B (chimera B) in two out of three
experiments, while indirect presentation of the PTK2B epitope in
the context of full-length PI4K2B (chimera A) was diminished as
compared to wild-type PTK2B. These data suggest that intercellu-
lar transfer of PTK2B is not dependent on the T-cell epitope, but
rather on characteristics of the full-length protein.
To investigate the mechanism of intercellular antigen transfer
in more detail, we constructed a vector encoding a chimeric pro-
tein consisting of full-length PTK2B and PI4K2B linked by a T2A
sequence (chimera C; Fig. 3A). In addition, His-tags were fused
to the N-terminus of PTK2B and C-terminus of PI4K2B to allow
detection of both proteins by the same anti-His antibody. T-cell
experiments again demonstrated intercellular transfer for the HLA
class II ligand of PTK2B, but not for the antigen from PI4K2B (Fig.
3B). Moreover, expression of PTK2B as detected on Western blot
by an anti-His antibody was stronger than for PI4K2B (Supporting
Information Fig. 3). These data indicate that cellular abundance of
PTK2B is dependent on its protein sequence and that high expres-
sion of PTK2B as compared to PI4K2B cannot be explained by a
difference in transcriptional activity or binding affinity of specific
antibodies.
In an attempt to determine which protein sequences are
required for intercellular transfer of the HLA class II ligand of
PTK2B, two other chimeric proteins were constructed. The con-
struct for chimera D encoded full-length PI4K2B fused to the C-
terminal 207 aa of PTK2B and the construct for chimera E encoded
the N-terminal 90 aa of PI4K2B fused to full-length PTK2B (Fig.
4A). Both fusion proteins contained the PI4K2B and PTK2B T-
cell epitopes as well as specific antibody epitopes at their N- and
C-terminal regions, respectively. T-cell experiments demonstrated
intercellular transfer of the HLA class II ligand of PTK2B upon co-
culture of HeLa cells transduced with chimera D or E with EBV-B
acceptor cells (Fig. 4B; left). T-cell recognition of chimera D was
lower than chimera E, which correlated with expression of the
fusion proteins on Western blot (Supporting Information Fig. 4).
Furthermore, the data for chimera E demonstrated that the HLA
class II ligand of PI4K2B can be transferred between cells when
fused to full-length PTK2B (Fig. 4B; right). In conclusion, the data
showed that intercellular transfer of natural HLA class II ligands
that are created by genetic variants is mediated by other protein
sequences than the T-cell epitope and cannot be explained by high
binding affinity of the T-cell epitope for its HLA restriction allele
or high avidity of the antigen-specific T-cell.
Intercellular transfer of the HLA class II ligand of
PTK2B is mediated by extracellular vesicles
To investigate whether intercellular transfer of the HLA class II lig-
and of PTK2B is mediated by EV, culture supernatants from HeLa
cells transduced with wild-type PTK2B were subjected to differen-
tial high speed ultracentrifugation and the 100 000 × g pellet was
loaded on EBV-B acceptor cells. T-cell experiments demonstrated
recognition of the 100 000 × g pellet, whereas the EV-depleted
supernatant collected after 100 000× g centrifugationwas not rec-
ognized (Fig. 5). The 100 000 × g pellet was confirmed to contain
EV by Western blot, characterized by enrichment of tetraspanin
CD9, absence of ER resident glycoprotein 96 (gp96) and pres-
ence of chaperone hsc70 (Supporting Information Fig. 5A), as
well as by electron microscopy (Supporting Information Fig. 5B).
As expected from T-cell recognition data, we also detected wild-
type PTK2B in the 100 000 × g pellet (Supporting Information
Fig. 5A). Similarly, all chimeric proteins for which intercellular
transfer was observed in T-cell experiments (chimeras B, D and
E) could be detected in 100 000 × g pellets from culture super-
natants from HeLa cells transduced with the respective chimeric
genes, whereas chimera A and wild-type PI4K2B, for which no
transfer was observed, were not present (Supporting Information
Fig. 4). These data showed that intercellular transfer of the HLA
class II ligand of PTK2B is mediated by structures present in 100
000 × g pellets.
EV populations in 100 000 × g pellets are often contaminated
with (nucleo)protein complexes. Therefore, to confirm that inter-
cellular antigen transfer is mediated by EV, culture supernatant
from HeLa cells transduced with wild-type PTK2B was pelleted
at 100 000 × g, labeled with the fluorescent lipid bilayer dye
PKH67 and low density vesicles were separated from high den-
sity protein complexes using a density gradient [19]. A total of
12 fractions with densities between 1.34 and 1.06 g/mL were col-
lected and analyzed by high-resolution flow cytometry [20, 21].
The data indicated that PKH67 positive EV were most abundant
in low density fractions 6–9 (1.21–1.07 g/mL) and showed that
various EV subpopulations could be distinguished that differed in
light scattering values and PKH67 staining intensity (Supporting
C© 2018 The Authors. European Journal of Immunology published by
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Figure 2. Intercellular transfer of the HLA class II ligand of PTK2B is mediated by other protein sequences than the T-cell epitope. (A) Schematic
drawing of constructs encoding full-length PTK2B (dark gray) and PI4K2B (light gray) with exchanged T-cell epitopes. Chimera A contains full-
length PI4K2B with the T-cell epitope of PTK2B. Chimera B contains full-length PTK2B with the T-cell epitope of PI4K2B. T-cell epitopes are
indicated by hatched areas. (B) Antigen-negative EBV-B cells expressing HLA-DRB3*01:01/A*01:02 and DQB1*06:03/A*01:03 (Agneg/HLApos acceptor
cells) were transduced with chimera A or B and tested for T-cell recognition by IFN-γ ELISA. Results of duplicate wells pooled from three
independent experiments represented by open, gray and black symbols are shown for T cells for PTK2B (dots; left) and PI4K2B (triangles; right). (C)
Antigen-negative EBV-B cells expressing HLA-DRB3*01:01/A*01:02 and DQB1*06:03/A*01:03 (Agneg/HLApos acceptor cells) were loaded with culture
supernatants from HeLa cells transduced with wild-type PTK2B, wild-type PI4K2B, chimera A or chimera B. After overnight loading, T cells were
added and IFN-γ release was measured by ELISA. T cells for PTK2B (dots; left) were tested for reactivity against EBV-B cells loaded with culture
supernatants from HeLa cells transduced with wild-type PTK2B or chimera A. T cells for PI4K2B (triangles; right) were tested for reactivity against
EBV-B cells loaded with culture supernatants from HeLa cells transduced with wild-type PI4K2B or chimera B. Results of single or duplicate wells
pooled from three independent experiments represented by open, gray and black symbols are shown.
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Figure 3. Cellular abundance of PTK2B is dependent on its protein sequence. (A) Schematic drawing of a retroviral construct encoding chimera
C, which consists of full-length PTK2B (dark gray) and PI4K2B (light gray) both fused to His-tags and linked by a T2A sequence. T-cell epitopes
are indicated by hatched areas. (B) HeLa cells transduced with chimera C (Agpos/HLAneg donor cells) were cocultured with antigen-negative EBV-B
cells expressing HLA-DRB3*01:01/A*01:02 and DQB1*06:03/A*01:03 (Agneg/HLApos acceptor cells). T-cell recognition was measured by IFN-γ ELISA.
Results of duplicate wells pooled from three independent experiments represented by open, gray and black symbols are shown for T cells for
PTK2B (dots; left) and PI4K2B (triangles; right).
Information Fig. 6A). Western blot analysis using antibodies
against human CD9 and flotillin also indicated the enrichment
of EV in fractions 7–9 (Supporting Information Fig. 6B). We next
determinedwhether intercellular transfer of theHLA class II ligand
of PTK2B was mediated by EV. The various density fractions were
loaded on EBV-B acceptor cells and T-cell recognition was mea-
sured to assess antigen presentation. PTK2B antigen recognition,
as measured by IFN-γ release by specific T cells, was predominant
in the EV containing fractions 6–7 (1.21–1.16 g/mL), confirming
that intercellular transfer of the HLA class II ligand of PTK2B is
mediated by EV (Supporting Information Fig. 6C). T-cell reactiv-
ity to transferred PTK2B was not observed upon incubation with
material present in fractions 2 and 9–12. Interestingly, the peak
in T-cell recognition was slightly shifted compared to the peak
in number of EV, suggesting that the PTK2B antigen resides in a
subpopulation of EV.
In conclusion, our data showed indirect antigen presentation
for a subset of natural HLA class II ligands that are created by
genetic variants and demonstrated that these antigens can be
transferred between cells by full-length proteins that are secreted
in EV.
Discussion
Priming of naive CD4 T cells by professional APC is a crucial
step in the initiation of a potent immune response. The HLA class
II processing pathway is perfectly equipped to efficiently present
exogenous threats to CD4T-cell surveillance [2]. However, when it
comes to intracellular dangers such as viruses or malignant trans-
formation in HLA class II-negative cells, efficient CD4 T-cell prim-
ing requires antigen release by cellular death or active transport of
intracellular antigens to professional APC. We here demonstrate
that certain cytosolic proteins can be actively transferred between
viable cells and that transfer of natural HLA class II ligands can
be mediated by EV. EV were isolated by a density gradient, which
is essential to separate EV from contaminating non-EV associated
protein complexes [19, 22, 23]. Our results confirmed previous
data showing that EV harbor a distinctive set of cellular proteins
and that T cells can simultaneously release EV subpopulations that
differ in molecular composition and are likely formed via different
biogenesis pathways [24].
Most viral infections and malignant transformations do not
occur in professional APC. As such, transport of foreign or mutated
cytosolic proteins from infected or transformed cells to profes-
sional APC is beneficial or even essential for efficient induction of
cellular immunity. For CMV and influenza, it has been shown that
viral proteins are transported from infected cells to professional
APC via secreted vesicles, and that this leads to activation of CD4
T cells [25, 26]. It is now well established that most cell types
release EV and that these vesicles can be isolated from body flu-
ids, such as ascites, pleural effusion, urine, breast milk and serum,
emphasizing their existence in vivo [21, 27–29]. Also tumor cells
release EV and their downstream effects are diverse [30]. Sev-
eral studies show immunosuppressive properties, but there is also
considerable evidence for immunosupportive effects [31], which
might be explained by antigen transfer and presentation to T cells
with different regulatory or effector functions.
For MHC class I restricted tumor antigens it has been reported
by Wolfers et al. [22] that immunization of mice with tumor-
derived EV was more potent in tumor rejection than vaccination
with tumor lysates or apoptotic bodies. They also demonstrated
C© 2018 The Authors. European Journal of Immunology published by
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Figure 4. Intercellular transfer of the HLA class II ligand of PTK2B by chimeric PI4K2B-PTK2B fusion proteins. (A) Schematic drawing of PI4K2B -
PTK2B fusion proteins. Chimera D consists of full-length PI4K2B (light gray) fused to the C-terminal 207 aa of PTK2B (dark gray), whereas chimera E
consists of the N-terminal 90 aa of PI4K2B (light gray) fused to full-length PTK2B (dark gray). T-cell epitopes of the respective proteins are indicated
by hatched areas. Arrows indicate the binding sites of antibodies used for detection of PI4K2B and PTK2B onWestern blot. (B) HLA class II-negative
HeLa cells transduced with wild-type PTK2B, wild-type PI4K2B, chimera D or chimera E (Agpos/HLAneg donor cells) were cocultured with antigen-
negative EBV-B cells expressing HLA-DRB3*01:01/A*01:02 and DQB1*06:03/A*01:03 (Agneg/HLApos acceptor cells). T-cell recognition was measured
by IFN-γ ELISA. Results of single or duplicate wells pooled from three independent experiments represented by open, gray and black symbols are
shown for T cells for PTK2B (dots; left) and PI4K2B (triangles; right).
Figure 5. Intercellular transfer of the HLA class II ligand of PTK2B
is mediated by the 100 000 × g pelletable fraction of cell culture
conditioned medium. HLA class II-negative HeLa cells transduced
with wild-type PTK2B (Agpos/HLAneg donor cells) were cocultured with
antigen-negative EBV-B cells expressing HLA-DRB3*01:01/A*01:02 and
DQB1*06:03/A*01:03 (Agneg/HLApos acceptor cells). Acceptor cells were
also loaded with the 100 000 × g pellet and EV-depleted supernatant of
cell culture conditionedmedium fromHeLa cells transduced with wild-
type PTK2B. After overnight incubation, T cells were added and IFN-γ
release was measured by ELISA. Results of single, duplicate or tripli-
cate wells pooled from three independent experiments represented by
open, gray and black dots are shown for T cells for PTK2B.
that differentiation antigen MART-1/Melan-A is sequestered as
full-length protein into EV and that this antigen can be cross
presented in APC and lead to CD8 T-cell activation. In line with
these findings, we here show that PTK2B is transferred between
cells as full-length protein in EV leading to antigen presentation
by HLA class II. In another mouse study in which different tumor
cell vaccines were compared for their immunogenicity, targeting
ovalbumin OVA to EV was shown to be superior in inducing CD8
T-cell mediated tumor rejection as compared to membrane bound
or soluble OVA [32]. Increased vaccine potency upon antigen tar-
geting to EV has also been supported by other studies [31, 33–35].
Our data demonstrate that the HLA class II ligand of PTK2B
is transferred between cells by the full-length protein in EV, but
it can be argued that PTKB is not integrated in EV but adheres
to the outside in a non-specific manner. Antigen transfer by non-
specific adherence to EV, however, is unlikely, since PTK2B is an
intracellular kinase and there is no evidence that it is secreted in
soluble form in the extracellular space. Moreover, in our exper-
iments, antigen transfer is measured between viable cells that
rapidly grow with low percentages of cell death. There is also
no evidence that PTK2B resides in the lumen of late endosomes
where EV are formed. Furthermore, for EV isolation from culture
supernatants, we used OptiPrep density gradient ultracentrifuga-
tion which outperforms other common isolation methods in terms
C© 2018 The Authors. European Journal of Immunology published by
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of recovery and purity of EV. EV isolated by OptiPrep density
gradient ultracentrifugation, for example, have been shown to
lack protein(-RNA) complexes, which contaminate EV prepara-
tions and confound functional assays [36].
In addition to PTK2B, we demonstrated indirect presentation of
theHLA class II ligand of DDX3Y (DBY), which is a protein encoded
by a male-specific gene on the Y-chromosome. It has already been
shown some years ago that this protein can lead to CD4 T-cell
mediated tumor rejection independent of MHC class II expression
on the tumor [12]. Furthermore, recipient derived DDX3Y pre-
sented on donor APC has been reported to induce CD4 T-cell medi-
ated graft-versus-host disease in mice [37]. CD4 T-cell mediated
rejection of MHC class II-negative tumors requires several steps.
First, antigens should be transferred from MHC class II-negative
tumor cells to MHC class II-positive APC. We here showed direct
evidence that DDX3Y can be transferred between cells. This is
supported by studies in female mice developing a DDX3Y-specific
CD4 T-cell response when injected with EV from male cells [38].
In a next step, activated CD4 T cells need to recruit other effec-
tor cells in order to mediate rejection of MHC class II-negative
tumor cells [10–12]. In mouse models macrophages and NK-cells
have been suggested to play a role, but also other immune cells
might be of importance. Further studies are required to elucidate
whether one special type of immune cell plays a crucial role in
rejection of MHC class II-negative tumors or whether it is medi-
ated by an orchestrated immune response with the CD4 T-cell as
central regulator.
In conclusion, we showed indirect antigen presentation for
a subset of natural HLA class II ligands and demonstrated that
(neo)antigens can be transferred between cells by full-length pro-
teins that are secreted in EV. Indirect antigen presentation has
been shown to mediate beneficial but also detrimental effects, and
it is therefore relevant to take intercellular transfer into consid-
eration when selecting (neo)antigens for cellular immunotherapy
or vaccination.
Materials and methods
Cell culture
Cervix carcinoma HeLa and EBV-B cell lines were cultured
in IMDM (Lonza BioWhittaker, Basel, Switzerland) with 10%
FCS (Cambrex, Verviers, Belgium), 1% penicillin/streptomycin
(Lonza) and 1.5% L-glutamine (Lonza). CD4 T-cell clones were
cultured in IMDM with 5% human serum, 5% FCS and 100 IU/mL
IL-2 (Chiron, Ringskiddy, Ireland), and restimulated every 10–20
days with irradiated allogeneic PBMC and 0.8 μg/mL PHA (Oxoid,
Cambridge, UK) [15]. For isolation of EV, HeLa cells were cul-
tured in serum-free IMDM with 1% penicillin/streptomycin, 1.5%
L-glutamine, 5 μg/mL insulin (Sigma-Aldrich B.V., Zwijndrecht,
The Netherlands), 5 μg/mL transferrin (Invitrogen, Breda, The
Netherlands), 5 ng/mL EGF (PeproTech, Rocky Hill, NJ), 100 nM
hydrocortisone (Sigma-Aldrich B.V.) and 20 ng/mL FGF2 (Biaffin
GmbH & Co KG, Kassel Niederzwehren, Germany) [39].
Antibodies
Flow cytometry was performed on a FACS Calibur (BD Bio-
sciences, Breda, The Netherlands) and cell sorting on a FACS Aria
(BD) using PE-labeled monoclonal antibodies against HLA-A2
(BB7.2; BD Pharmingen, San Diego, CA), HLA-DR (L243; BD),
HLA-DQ (1a3; Meridian Life Science, Saco, ME), NGFR (C40-
1457; BD Pharmingen) or CD20 (L27; BD). For Western blotting,
mouse antibodies against hsc70 (sc-7298; Santa Cruz Biotech-
nology, Santa Cruz, CA), gp96 (ab63469; Abcam, Cambridge,
UK), 6xHis (ab18184; Abcam), and rabbit antibodies against
CD9 (ab65230; Abcam), PTK2B (ab24798; Abcam) and PI4K2B
(ab37812; Abcam) were used. As secondary antibodies, biotiny-
lated goat anti-mouse or anti-rabbit antibodies (Invitrogen) were
used and visualized by Streptavidin-QDots 625 (Invitrogen) under
UV illumination. For detection of EV, mouse antibodies against
human CD9 (HI9a, BioLegend, Fell, Germany) and flotillin-1
(clone 18, BD Biosciences, San Jose, CA, USA) were used.
Retroviral constructs and transduction
HLA-DQB1*06:03, DQB1*05:01, DQA*01:03 and DQA*01:01
were cloned in separate pLZRS vectors with truncated nerve
growth factor receptor (NGFR) as marker gene for DQB chains
and enhanced green fluorescence protein (EGFP) for DQA chains.
HLA-DRB1*03:01, DRB1*13:01, DRB3*01:01, DRB3*02:02 and
DRA*01:02 were cloned in MP71 vectors with NGFR [14, 15,
18]. HLA class II-negative HeLa cells transduced with HLA class
II were sorted on HLA-DR or -DQ surface expression. EBV-B cells
transduced with HLA-DRB or -DQBwere sorted onNGFR expres-
sion. The genes encoding full-length PTK2B, MR1, PI4K2B and
MTHFD1 were cloned in MP71 with human CD20 as marker gene.
Full-length DBY was cloned in pLZRS containing EGFP. Chimeric
and mutated constructs were cloned by two-step PCR. Chimera A
contained full-length PI4K2B (NM 018323) with its T-cell epitope
at 220–262 bp replaced by the PTK2B epitope. Chimera B con-
tained full-length PTK2B (NM 173175) with its T-cell epitope at
2371–2410 bp replaced by the PI4K2B epitope. Chimera D con-
tains full-length PI4K2B fused to the last 621 bp of PTK2B. Chimera
E contains the first 270 bp of PI4K2B fused to full-length PTK2B.
Chimeric constructs A, B, D and E were cloned in MP71 with CD20
as marker gene. For construct C, 6xHis-tags were fused to the N-
terminus of PTK2B and C-terminus of PI4K2B and both sequences
were linked with a T2A sequence. The His-PTK2B-T2A-PI4K2B-His
sequence was cloned in MP71 with EGFP as marker gene. All con-
structs were verified by DNA sequencing. Retroviral supernatants
were obtained by transfecting nx-A packaging cells and cells
were transduced with viral supernatants in culture plates coated
with recombinant human fibronectin CH 296 (Takara Shuzo, Otsu,
Shiga, Japan) [40].
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Antigen presentation assays
Stimulator cells (10 000 or 30 000 cells/well) were co-incubated
with CD4 T cells (5000 cells/well) overnight at 37°C in 96-well
plates. As CD4 T cells, clones for PI4K2B [14], PTK2B [15],
MTHFD1 [15], LY75 [15], MR1 [15] and DBY [18] were used. In
intercellular transfer experiments, donor and acceptor cells were
plated at 1:1 ratios in 96-wells plates overnight before adding the
T cells. As acceptor cells, HeLa cells transduced with LZRS encod-
ing the invariant chain and human CD80 as marker gene was
used. HeLa-Ii cells have been demonstrated to efficiently process
and present HLA class II ligands [41]. For loading with recombi-
nant proteins, E.coli with a pKE-1 vector encoding the respective
antigen under an IPTG-inducible promoter were grown to OD600
of 0.5 with 50 μg/mL ampicillin (Sigma-Aldrich B.V.) and protein
expression was induced by 1 mM IPTG for 4 h (Promega, Madi-
son,WI). Subsequently, bacteria were opsonized by adding human
serum with 17% (vol/vol) complement (Sigma-Aldrich B.V.) for
1 h. Target cells were pulsed with complement-opsonized bacteria
in IMDMwith 10% FCS and 30μg/mL gentamycin (Sigma-Aldrich
B.V.) overnight at 37°C before T cells were added. Culture super-
natants were depleted of cells by centrifugation with 300 × g for
10 min and separated through 5, 30 (Vivaproducts, Littleton, MA)
or 100 (Millipore, Amsterdam, The Netherlands) kDa filters. Con-
centrated flow through fractions (50 μL) or isolated 100 000 × g
fractions (50 μL) were loaded on target cells in 96-well plates
overnight before T cells were added. Cytokine release was mea-
sured in 50 μL supernatants by IFN-γ ELISA (Sanquin, Burton
upon Trent, UK).
Western blot analysis
Cells were harvested, washed with PBS and resuspended in 1%
Triton-X (Sigma-Aldrich B.V.) lysis buffer containing protease
inhibitors (Roche, Woerden, The Netherlands) for 20 min on ice.
Whole cell lysates were obtained after centrifugation at 10 000× g
for 30 min. Protein concentration was assessed by the Brad-
ford assay (Bio-Rad Laboratories B.V., Veenendaal, The Nether-
lands). SDS-Page was run with 10–25 μg protein in each lane on
precast NuPage
R©
Novex 10% Bis-Tris Mini gels (Invitrogen) for
35 min at 30V under denaturing conditions. Gels were blotted on
PVDF membranes using XCell SureLock
R©
Mini-Cell blotting sys-
tem (Invitrogen), blocked overnight with 5% BSA in PBS with
0.05% Tween-20 and subsequently incubated with primary anti-
body, biotinylated secondary antibody and streptavidin-QDots 625.
Each incubation step was performed for 1 h at RT. Antibody bind-
ing was visualized under UV illumination.
Isolation of extracellular vesicles
HeLa cells were grown in serum-free medium for 3 days.
Culture supernatant was depleted of cells by centrifugation at
300 × g for 10 min. Supernatants were subsequently depleted
of cellular debris by centrifugation at 3000 × g for 20 min,
followed by centrifugation at 10 000 × g for 30 min. Finally,
supernatants were centrifuged at 100 000 × g for 15 h, pellets
were resuspended in PBS and centrifuged again at 100 000 × g
for 15 h in a Beckman-Coulter SW28 rotor. Pellets collected at
100 000 × g were resuspended in 150–200 μL culture medium
for T-cell experiments, 50 μL 1% Triton-X lysis buffer for Western
blot analysis or PBS/4% glutaraldehyde (Brunschwig Chemie,
Amsterdam, The Netherlands) for analysis by transmission
electron microscopy. For isolation of EV by density gradient ultra-
centrifugation, supernatants were centrifuged at 100 000 × g for
1.05 h, pellets were washed in PBS and centrifuged again at 100
000 × g for 1.05 h in a SW28 rotor. Pelleted particles were stained
with PKH67 (Sigma Aldrich, Zwijndrecht, The Netherlands) as
described previously [20, 21]. Pellets were transferred to SW40
tubes and mixed with 1.5 mL 60% OptiPrep (Progen, Heidelberg,
Germany) and overlayed with 15 additional OptiPrep fractions
ranging from 50 to 10% in increments of 700 μL. Density
gradients were centrifuged for 16 h at 192 000 × g in a SW40Ti
rotor in a Beckman Coulter Optima L-90K ultracentrifuge. A total
of 12 fractions (1.34-1.06 g/mL) were collected. Each fraction
was diluted 10-fold and loaded on EBV-B cells. After overnight
incubation, EBV-B cells were washed and antigen recognition by
CD4 T cells was measured by IFN-γ ELISA. The BD InfluxTM flow
cytometer (Becton Dickinson, Breda, The Netherlands) with opti-
mized configuration was used for high resolution flow cytometric
analysis of vesicles in different density fractions as described
previously [20]. The system was triggered on PKH67 fluorescence
signals derived from the EV and thresholding on this fluores-
cence channel allowed discrimination between EV and noise
events.
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